Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company’s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company’s website.
Details of the webcast and conference call:
Webcast link: https://edge.media-server.com/mmc/p/73gzxc8m
Conference call registration link: https://register.vevent.com/register/BIbb8ec3d3557e47e3a4db7b8c03339124
About Silence Therapeutics
Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213336305/en/
Inquiries:
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Source: Silence Therapeutics plc